Back the Breakthrough. Redefine Treatment. With Us.

5.4 million bites and 2.7 million serious envenomings each year, with venomous species present in more than 90% of countries globally

Recognised by the WHO as a priority neglected tropical disease with dedicated 2030 targets to halve the global burden

The first meaningful breakthrough in more than a century, with an oral combination therapy designed to enable early intervention at the point of need, addressing the critical limitations of antivenom-based care

Oral, heat-stable format with no IV or cold-chain dependency, enabling immediate treatment in remote areas where 80% of bites occur

Multi-pathway inhibition designed to work across medically significant species, solving the species-identification problem that limits current treatments

Our approach targets tissue-destroying enzymes (metalloproteases and phospholipase A2), designed to prevent the lifelong disabilities that antivenom cannot address, with no existing product offering dual-site action

Built on research from the University of Reading and led by an internationally recognised venom pharmacologist and researchers with an expanding evidence base behind the lead programme

Robust mechanistic rationale targeting the most conserved and destructive pathways across snake venoms, validated through extensive preclinical work

Preclinical validation across 70+ venoms covering the major medically significant species responsible for global snakebite burden

Clear regulatory strategy with accelerated clinical pathways due to the critical unmet medical need and orphan drug potential

A defined regulatory strategy with strategic groundwork already underway in our priority launch regions, designed for rapid market penetration

Defined regulatory pathways including accelerated approval opportunities through orphan drug designation and priority review mechanisms

Strategic partnership in India supporting early market entry in the world's largest snakebite burden country with established distribution channels

Tiered expansion strategy designed to scale through LMICs where the burden is highest, then into developed markets to support global access and long-term sustainability

Designed from day one for global deployment, with manufacturing economics that support reach into the regions most affected

Low-cost, scalable small-molecule manufacturing enables affordable pricing for LMIC markets while maintaining strong margins needed to expand access globally

Pipeline expansion into veterinary markets and adjacent toxin-related indications, creating multiple applications from the same core technology

Strong intellectual property portfolio around novel combinations and applications, with freedom to operate in key global markets

Snakebite is a recognised priority neglected tropical disease, and our work sits squarely within an expanding global health agenda

Aligned with WHO 2030 targets to halve the global burden, with increasing government and NGO funding committed to snakebite solutions

Growing policy focus through national snakebite strategies, particularly in high-burden countries like India, Nigeria, and Brazil